{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:33:17Z","timestamp":1788838397576,"version":"build-2803163510"},"reference-count":51,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Res (Stuttg)"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background Some studies indicate that the angiogenesis process is related to vascular endothelial growth factor, which can interact with endothelial cell surface receptors (VEGF-R1, VEGF-R2, and VEGF-R3); this biochemical process and other factors result in the promotion and growth of new blood vessels under normal conditions. However, some studies indicate that this phenomenon could also occur in cancer cells. It is important to mention that some amino derivatives have been prepared as VEGF-R1 inhibitors; however, their interaction with VEGF-R1 is not clear, perhaps due to different experimental approaches or differences in their chemical structure.<\/jats:p>\n                  <jats:p>Objective The aim of this study was to evaluate the theoretical interaction of several amino-nitrile derivatives (Compounds 1 to 38) with VEGF-R1.<\/jats:p>\n                  <jats:p>Methods The theoretical interaction of amino-nitrile derivatives with VEGF-R1 was carried out using the 3hng protein as the theoretical model. In addition, cabozantinib, pazopanib, regorafenib, and sorafenib were used as controls in the DockingServer program.<\/jats:p>\n                  <jats:p>Results The results showed different amino acid residues involved in the interaction of amino-nitrile derivatives with the 3hng protein surface compared with the controls. In addition, the inhibition constant (Ki) was lower for Compounds 10 and 34 than for cabozantinib. Other results show that Ki for Compounds 9, 10, 14, 27\u201329 and 34\u201336 was lower in comparison with pazopanib, regorafenib, and sorafenib.<\/jats:p>\n                  <jats:p>Conclusions All theoretical data suggest that amino-nitrile derivatives could produce changes in the growth of some cancer cell lines through VEGFR-1 inhibition. Therefore, these amino-nitrile derivatives could be a therapeutic alternative to treat some types of cancer.<\/jats:p>","DOI":"10.1055\/a-2062-3571","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T19:36:02Z","timestamp":1683920162000},"page":"355-364","source":"Crossref","is-referenced-by-count":13,"title":["Interaction of Some Amino-Nitrile Derivatives with Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) Using a Theoretical Model"],"prefix":"10.1055","volume":"73","author":[{"given":"Lauro","family":"Figueroa-Valverde","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University Autonomous of Campeche, Campeche, Camp., M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"D\u00edaz-Cedillo","sequence":"additional","affiliation":[{"name":"Escuela Nacional de Ciencias Biol\u00f3gicas del Instituto Polit\u00e9cnico Nacional. Santo Tomas, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Rosas-Nexticapa","sequence":"additional","affiliation":[{"name":"Facultad de Nutrici\u00f3n, Universidad Veracruzana, M\u00e9dicos y Odontologos, Unidad del Bosque Xalapa Veracruz, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Alvarez-Ramirez","sequence":"additional","affiliation":[{"name":"Facultad de Nutrici\u00f3n, Universidad Veracruzana, M\u00e9dicos y Odontologos, Unidad del Bosque Xalapa Veracruz, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Virginia","family":"Mateu-Armad","sequence":"additional","affiliation":[{"name":"Facultad de Nutrici\u00f3n, Universidad Veracruzana, M\u00e9dicos y Odontologos, Unidad del Bosque Xalapa Veracruz, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"L\u00f3pez-Ramos","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University Autonomous of Campeche, Campeche, Camp., M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"L\u00f3pez-Gutierrez","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaco-Chemistry, Faculty of Chemical Biological Sciences, University Autonomous of Campeche, Campeche, Camp., M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1056\/NEJM199007053230106","article-title":"Regulatory functions of the vascular endothelium","volume":"323","author":"J Vane","year":"1990","journal-title":"New Eng J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1023\/A:1012259529167","article-title":"Endothelium in vitro: a review of human vascular endothelial cell lines for blood vessel-related research","volume":"4","author":"D Bou\u00efs","year":"2001","journal-title":"Angiogenesis"},{"key":"ref3","first-page":"1","article-title":"Extracellular vesicles derived from hypoxia-preconditioned olfactory mucosa mesenchymal stem cells enhance angiogenesis via miR-612","volume":"19","author":"L Ge","year":"2021","journal-title":"J Nanobiotech"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.121.054071","article-title":"Role of venous endothelial cells in developmental and pathologic angiogenesis","volume":"144","author":"H Lee","year":"2021","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41390-020-01177-9","article-title":"The role of integrins in inflammation and angiogenesis","volume":"89","author":"O Mezu-Ndubuisi","year":"2021","journal-title":"Pediat Res"},{"key":"ref6","first-page":"1","article-title":"Exosomes derived from pioglitazone-pretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis","volume":"19","author":"Y Hu","year":"2021","journal-title":"J Nanobiotech"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3390\/cancers13050942","article-title":"Prostaglandin E2 receptor 4 (EP4) as a therapeutic target to impede breast cancer-associated angiogenesis and lymphangiogenesis","volume":"13","author":"G Depaz- Linares","year":"2021","journal-title":"Cancers"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","article-title":"Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis","volume":"4","author":"M Shibuya","year":"2006","journal-title":"Angiogenesis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"16986","DOI":"10.1074\/jbc.M000528200","article-title":"Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells","volume":"275","author":"N Rahimi","year":"2000","journal-title":"J Biol Chem"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.1158\/0008-5472.CAN-10-1138","article-title":"Differential effects of VEGFR-1 and VEGFR-2 inhibition on tumor metastases based on host organ environment","volume":"70","author":"Y Lee","year":"2010","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"599281","DOI":"10.3389\/fcell.2020.599281","article-title":"Molecular bases of VEGFR-2-mediated physiological function and pathological role","volume":"8","author":"X Wang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","article-title":"Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis","volume":"9","author":"M Shibuya","year":"2006","journal-title":"Angiogenesis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"P Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.7150\/ijbs.70958","article-title":"VEGF\/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: targeting the tumor microenvironment","volume":"18","author":"Y Zhao","journal-title":"Int J Biol Sci 2922"},{"key":"ref15","first-page":"118","article-title":"The Effect of Eight-week Concurrent Training On The Plasma And Gene Expression Levels VEGFR-1 and VEGFR-2 in Men with Prostate Cancer","volume":"8","author":"H Beigom","year":"2020","journal-title":"J Neyshabur Univ Med Sci"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR Axis Revisited: Implications for Cancer Therapy","volume":"23","author":"P Mabeta","year":"2022","journal-title":"International J Mol Sci"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjc.6602374","article-title":"Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer","volume":"92","author":"H Bando","year":"2005","journal-title":"British J Cancer"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6602824","article-title":"Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells","volume":"93","author":"S Garvin","year":"2005","journal-title":"British J Cancer"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s12032-008-9052-4","article-title":"Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients","volume":"25","author":"Z Ustuner","year":"2008","journal-title":"Med Oncol"},{"key":"ref20","first-page":"359","article-title":"Expression of vascular endothelial growth factor (VEGF) and its receptors in human hepatocellular carcinoma cell lines","author":"H Wang","year":"2001","journal-title":"Chinese J Cell Mol Immun"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/jclinpath-2012-200721","article-title":"Expression and prognostic significance of vascular endothelial growth factor receptor 1 in hepatocellular carcinoma","volume":"65","author":"T Li","year":"2012","journal-title":"J Clin Pathol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1158\/1078-0432.CCR-22-0873","article-title":"FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer","volume":"28","author":"E Duke","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref23","first-page":"1324","article-title":"Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy","volume":"9","author":"B Sloan","year":"2008","journal-title":"Curr Opinion Invest drugs"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"S Wilhelm","year":"2006","journal-title":"Nature Rev Drug Dis"},{"key":"ref25","first-page":"1303","article-title":"Molecular targeted therapies for cancer: sorafenib monotherapy and its combination with other therapies","volume":"27","author":"N Ibrahim","year":"2012","journal-title":"Oncol Rep"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"105011","DOI":"10.1016\/j.bioorg.2021.105011","article-title":"The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020","volume":"113","author":"X Liang","year":"2021","journal-title":"Bioorg Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","volume":"20","author":"T Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref28","first-page":"e152","article-title":"Efficacy and safety comparison of regorafenib and fruquintinib in metastatic colorectal cancer-an observational cohort study in the real world","volume":"21","author":"Q Zhang","year":"2022","journal-title":"Clin Col Cancer"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2021.10.033","article-title":"Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and\/or metastatic salivary gland cancer","volume":"161","author":"W Van-Boxtel","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1007\/s12325-020-01477-w","article-title":"Safety profile and adverse events of special interest for Fruquintinib in Chinese patients with previously treated metastatic colorectal cancer: Analysis of the phase 3 FRESCO trial","volume":"37","author":"J Li","year":"2020","journal-title":"Adv Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19103258","article-title":"Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension","volume":"19","author":"R Milling","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref32","first-page":"99","article-title":"Efectividad y seguridad de regorafenib y trifluridina\/tipiracilo en c\u00e1ncer colorrectal metast\u00e1tico","volume":"30","author":"M Arrieta","year":"2020","journal-title":"Rev OFIL"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-017-1678-1","article-title":"New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management","volume":"21","author":"F Kroschinsky","year":"2017","journal-title":"Critical Care"},{"key":"ref34","first-page":"5687","article-title":"Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors","volume":"45","author":"P Manley","year":"2002","journal-title":"J Mic Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1021\/jm901388c","article-title":"Identification of 2-anilino-9-methoxy-5, 7- dihydro-6 H-pyrimido [5, 4-d][1] benzazepin-6-ones as dual PLK1\/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation","volume":"53","author":"A Egert-Schmidt","year":"2010","journal-title":"J Med Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"R K Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1007\/s11030-022-10406-8","article-title":"A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy","volume":"26","author":"P Shiri","year":"2022","journal-title":"Mole Diver"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.canlet.2018.10.032","article-title":"Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer","volume":"442","author":"Y Zhang","year":"2019","journal-title":"Cancer Lett"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"131507","DOI":"10.1016\/j.molstruc.2021.131507","article-title":"Vibrational spectral analysis of Sorafenib and its molecular docking study compared to other TKIs","volume":"1248","author":"L St\u0103ncioiu","year":"2022","journal-title":"J Mol Struct"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/vjch.202100128","article-title":"Design and synthesis of two Strychnidin-oxiran-naphthalenol derivatives and their theoretical evaluation as noradrenaline and serotonin reuptake inhibitors","volume":"60","author":"L Figueroa-Valverde","year":"2022","journal-title":"Vietnam J Chem"},{"key":"ref41","first-page":"1","article-title":"Synthesis and Theoretical Interaction of 3-(2-oxabicyclo [7.4. 0] trideca-1 (13), 9, 11-trien-7-yn-12-yloxy)-steroid Derivative with 17\u03b2-hydroxysteroid Dehydrogenase Enzyme Surface","volume":"13","author":"L Figueroa-Valverde","year":"2023","journal-title":"Biointerface Res Appl Chem"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"132712","DOI":"10.1016\/j.molstruc.2022.132712","article-title":"An overview on applications of SwissADME web tool in the design and development of anticancer, antitubercular and antimicrobial agents: A medicinal chemist\u2019s perspective","author":"B Bakchi","year":"2022","journal-title":"J Mol Struc"},{"key":"ref43","first-page":"1","article-title":"In silico approach for the development of phenolic derivatives as potential anti-angiogenic agents against lysyl oxidase-like 2 enzyme","volume":"8","author":"M Aqeel","year":"2022","journal-title":"Future J Pharma Sci"},{"key":"ref44","first-page":"8471","article-title":"Virtual screening in pharmacokinetics, bioactivity, and toxicity of the amburana cearensis secondary metabolites","volume":"12","author":"M Da-Rocha","year":"2022","journal-title":"Biointerface Res Appl Chem"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/jm800790t","article-title":"Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors","volume":"52","author":"P Renhowe","year":"2009","journal-title":"J Med chem"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1080\/14756366.2018.1503654","article-title":"Design, synthesis, and screening of orthoamino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2 Inhibitors","volume":"33","author":"M Abd-Elhameid","year":"2018","journal-title":"J Enz Inh Med Chem"},{"key":"ref47","first-page":"1","article-title":"Discovery of 8-amino-substituted 2-phenyl-2, 7- naphthyridinone derivatives as new c-kit\/vegfr-2 kinase inhibitors","volume":"24","author":"H Sun","year":"2019","journal-title":"Molecules"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/cbic.200300748","article-title":"Design, Synthesis, and Biological Evaluation of Aminoboronic Acids as Growth-Factor Receptor Inhibitors of EGFR and VEGFR -1 Tyrosine Kinases","volume":"5","author":"T Asano","year":"2004","journal-title":"ChemBioChem"},{"key":"ref49","first-page":"1","article-title":"A highly accurate metadynamics-based Dissociation Free Energy method to calculate protein-protein and protein-ligand binding potencies","volume":"12","author":"J Wang","year":"2022","journal-title":"Sci Rep"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1021\/acs.jcim.1c01445","article-title":"Pre-exascale computing of protein-ligand binding free energies with open source software for drug design","volume":"62","author":"V Gapsys","year":"2022","journal-title":"J Chem Inf Mod"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.51847\/wRqL2guumm","article-title":"Evaluation of Interaction of Some Quinolone Derivatives on RSK-4 Using a Theoretical Model","volume":"11","author":"M Rosas-Nexticapa","year":"2022","journal-title":"Clin Inv Cancer J"}],"container-title":["Drug Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2062-3571.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T05:11:40Z","timestamp":1729401100000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2062-3571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":51,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2023,7,5]]},"published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2062-3571","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2194-9379","2194-9387"],"issn-type":[{"value":"2194-9379","type":"print"},{"value":"2194-9387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]}}}